| Literature DB >> 26692884 |
Felistas Mashinya1, Marianne Alberts1, Jean-Pierre Van Geertruyden2, Robert Colebunders2.
Abstract
BACKGROUND: The risk of cardiovascular diseases (CVD) in human immunodeficiency virus (HIV) infected people on antiretroviral therapy (ART) from some rural parts of Africa is not well known. We assessed CVD risk factors, the estimated 5-year Data collection on adverse effects of anti-HIV drugs (DA.) risk score and the 10-year Framingham risk score in persons with HIV infection on ART in a rural area in South Africa.Entities:
Keywords: Antiretroviral therapy; Cardiovascular disease risk; Human immunodeficiency virus
Year: 2015 PMID: 26692884 PMCID: PMC4676091 DOI: 10.1186/s12981-015-0083-6
Source DB: PubMed Journal: AIDS Res Ther ISSN: 1742-6405 Impact factor: 2.250
Demographics, HIV information and CVD risk factors in ART treated HIV infected participants by gender
| All participants N = 214, n (%) | Females N = 171, n (%) | Males N = 43, n (%) | P-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 44.8 ± 11.8 | 43.5 ± 11.6 | 49.9 ± 11.1 |
|
| Unmarried | 164 (76.6) | 137 (80.1) | 27 (62.8) |
|
| Secondary education | 98 (45.8) | 83 (48.5) | 15 (34.9) | 0.12 |
| Unemployed | 149 (69.6) | 129 (75.4) | 20 (46.5) | 0.001 |
| HIV information | ||||
| CD4 count (cells/mm3) | 461.9 ± 235.3 | 485.5 ± 234.1 | 364.3 ± 216.6 |
|
| Viral load (copies/ml) | ≤50 | ≤50 | ≤50 | 0.14 |
| Mean duration of ART in months (N = 200) | 36.1 ± 24.4 | 37.0 ± 24.3 | 32.5 ± 24.6 | 0.31 |
| NVP (NNRTI)-based ART* | 25 (12.5) | 22 (13.8) | 3 (7.5) | |
| EFV (NNRTI)-based ART | 172 (86) | 136 (85.0) | 36 (90.0) | |
| Alluvia (PI)-based ART | 3 (1.5) | 2 (1.3) | 1 (2.5) | |
| CVD risk factors | ||||
| Tobacco use | 45 (21.1) | 28 (16.5) | 17 (39.5) |
|
| 47 (22.0) | 29 (17 %) | 18 (41.9 %) |
| |
| Alcohol use | 38 (24.2) | 37 (29.1 %) | 1 (3.3 %) |
|
| Fruit and vegetables intake (<5 servings/day) | 150 (95.5) | 121 (95.3) | 29 (96.7) | 1.00 |
| Obesity | 27 (12.7) | 25 (14.6) | 2 (4.8) | 0.12 |
| Abdominal obesity | 51 (23.9) | 44 (25.9) | 7 (16.3) | 0.23 |
| Hypertension | 56 (26.2) | 40 (23.4) | 16 (37.2) | 0.08 |
| Diabetes | 10 (4.7) | 6 (3.5) | 4 (9.3) | 0.12 |
| Low HDL | 91 (43.8) | 71 (42.3) | 20 (50.0) | 0.38 |
| Hypercholesterolaemia | 69 (33.2) | 58 (34.5) | 11 (27.5) | 0.46 |
| Hypertriglyceridaemia | 35 (16.8) | 21 (12.5) | 14 (35.0) |
|
| TC/HDL (≥5) | 28 (13.5) | 17 (10.1) | 11 (27.5) |
|
| High TG/HDL-C (≥1.49) | 38 (18.3) | 23 (13.7) | 15 (37.5) |
|
| ApoB/ApoA (≥0.68) | 93 (45.4) | 74 (44.8) | 19 (47.5) | 0.86 |
| Metabolic syndrome | 20 (9.6) | 15 (8.9) | 5 (12.5) | 0.56 |
Diabetes—glucose >7 mmol/l and/or history of diabetes, hypertension—systolic blood pressure >140 and/or diastolic blood pressure >90 or history of high blood pressure, abdominal obesity—waist circumference >88 cm for females and >102 cm for males, obesity—body mass index ≥30 kg/m2, low HDL ≤1.3 for females and 1.1 for males, hypercholesterolaemia—TC ≥ 5 mmol/l, hypertriglyceridaemia—TG ≥ 1.7 mmol/l, high TC/HDL-C >5, TG/HDL-C ≥ 1.49, high ApoB/ApoA >0.68
* ART information was available for 200 participants
ART antiretroviral therapy, HIV human immunodeficiency virus, NVP nevirapine, EFV efavirenz, CVD cardiovascular disease, ApoB apolipoprotein B, Apo A apolipoprotein A, TC total cholesterol, HDL-C high density lipoprotein cholesterol. MET-min/wk metabolic equivalent of task-minutes/week
Predictors of Metabolic CVD risk factors among ARV treated HIV infected people
| Predictor variable | Metabolic CVD risk factors | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HTN | Diabetes | Low HDL-C | High TC | High TG | High TC/ HDL-C | High Apo B/Apo A | High TG/HDL-C | Met S | |
| Age (years) | |||||||||
| ≤50 | 1 [reference] | 1 [reference] | 1 [reference] | – | 1 [reference] | 1 [reference] | 1 [reference] | 1[reference] | 1 [reference] |
| >50 |
|
|
|
|
| 1.70 (0.90–3.21) | 2.8 (0.84–5.68) |
| |
| Gender | |||||||||
| Females | – | 1 [reference] | – | – | – | 1 [reference] | – | 1 [reference] | – |
| Males | 1.83 (0.46–7.20) |
| 1.90 (0.21–17.6) | ||||||
| Alcohol use | |||||||||
| No | 1 [reference] | – | – | 1 [reference] | – | – | – | – | – |
| Yes | 0.57 (0.18–1.77) | 1.69 (0.85–3.36) | |||||||
| Tobacco use | |||||||||
| No | – | – | 1 [reference] | – | – | – | – | – | 1 [reference] |
| Yes | 0.49 (0.19–1.23) | 1.61 (0.30–8.70) | |||||||
| Log VL | |||||||||
| <1.71 | 1 [reference] | – | 1 [reference] | – | – | – | 1 [reference] | 1 [reference] | – |
| >1.71 |
|
|
| 2.71 (0.84–8.75) | |||||
| ARV-duration | |||||||||
| >60 months | 1 [reference] | – | – | – | 1 [reference] | 1 [reference] | – | 1 [reference] | 1 [reference] |
| 30–60 | 2.32 (0.65–8.34) | 0.48 (0.14–1.68) |
| 0.49 (0.13–1.87) | 0.48 (0.09–2.75) | ||||
| <30 months | 0.32 (0.66-8.19) | 0.45 (0.14–1.46) |
| 0.29 (0.07–1.23) | 0.34 (0.05–2.60) | ||||
| Abdominal obesity | |||||||||
| No | 1 [reference] | – | 1 [reference] | 1 [reference] | 1 [reference] | – | 1 [reference] | 1 [reference] | _ |
| Yes | 2.48 (0.69–8.89) | 1.10 (0.26–4.66) |
| 2.08 (0.75–5.82) | 1.71 (0.88–3.35) | 2.981 (1.05–8.47) | |||
| PA (MET-min/wk) | |||||||||
| >600 | 1 [reference] | – | 1 [reference] | – | – | – | – | – | – |
| <600 | 0.27 (0.07–1.09) | 0.54 (0.11–2.71) | |||||||
| CD 4 count | |||||||||
| >500 | – | – | – | – | – | – | – | – | 1 [reference] |
| 301–500 | 0.31 (0.05–1.96) | ||||||||
| ≤300 | 0.12 (0.01–1.29) | ||||||||
| F/veg intake | – | – | 0.92 (0.18–4.79) | – |
| – | – | 0.67 (0.41–1.10) | – |
| Abd. obesity by PA | – | – | 7.18 (0.74–69.7) | – | – | – | – | – | – |
| Gender by ARV months | |||||||||
| >60 | 1 [reference] | ||||||||
| 30–60 | – | – | – | – | – | – | – | 0.46 (0.02–10.9) | – |
| <30 | 6.07 (0.45–28.8) | ||||||||
| Classification accuracy | 81.7 % | 95.3 % | 67.8 % | 69.6 % | 84.1 % | 87.4 % | 61.8 % | 82.6 % | 91.0 % |
Values are reported as adjusted odds ratio (confidence interval)
PA physical activity, VL viral load, F/V fruit and vegetable intake, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, TC total cholesterol, TG triglycerides, Apo B apolipoprotein B, Apo A apolipoprotein A, Met S metabolic syndrome, HTN hypertension, ARV antiretroviral, MET-min/wk metabolic equivalent of task-minute/week, Abd abdominal
1 p-value < 0.05 is significant
* p = 0.05, marginally significant
Comparison between CVD risk estimation using DAD and Framingham equations
| Cardiovascular disease risk | FRAMINGHAM (N = 164) | |||
|---|---|---|---|---|
| Low risk (<10 %) | Moderate risk (10–20 %) | High risk (>20 %) | ||
| DAD (N = 164) | ||||
| Low risk (<10 %) | 113 | 0 | 0 | |
| Moderate risk (1–5 %) | 37 | 8 | 0 | |
| High risk and very high risk (>5 %) | 3 | 3 | 0 | |
| Agreement | 73.8 % | |||
| Kappa (p-value) | 0.23 (0.001) | |||
| 95 % CI for Kappa | 0.10–0.35 | |||
N number, DAD data collection on adverse effects of anti-HIV drugs, CVD cardiovascular disease, CI confidence interval